Medication info

Lansoprazole Capsule (Lansoprazole)

Prescription medicationHard capsuleOralExpired
Ingredient · strength
Lansoprazole›30mg / 1 capsule
Manufacturer / importer
Kips Bio Pharma Co., Ltd.
Appearance
A hard capsule filled with white granules that are white to light brown, with a green upper part and a white lower part.
Packaging
28 capsules/bottle
Approval status
Expired

MFDS item code 201405372 · Approved 2014.11.18

This product's status changed to Expired on 2024.11.18. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Treatment and prevention of gastroduodenal ulcers, Helicobacter pylori infection, gastroesophageal reflux disease, and excess gastric acid
Who takes it
Adults · Children
Adult dose
This medicine should be administered before meals. For patients who have difficulty swallowing the medicine, open the capsule, mix the contents into a small amount of (60 mL) orange juice or tomato juice, and administer immediately. To ensure that the entire dose is taken, rinse the glass with twice or more the amount of juice and drink immediately. After opening this medicine, do not chew or crush it before taking it. Short-term treatment of active duodenal ulcer: Administer lansoprazole 15 mg orally once daily for 4 weeks. Short-term treatment of active benign gastric ulcer: Administer lansoprazole 30 mg orally once daily for 8 weeks. Eradication of Helicobacter pylori to reduce recurrence of duodenal ulcer: Administer lansoprazole 30 mg with clarithromycin 250 ∼ 500 mg and amoxicillin 1,000 mg twice daily (every 12 hours) for 7 days. Administration may be continued for up to 14 days if necessary. Eradication of Helicobacter pylori to reduce recurrence of duodenal ulcer: Administer lansoprazole 30 mg in combination with amoxicillin 1,000 mg 3 times daily (every 8 hours) for 14 days. Maintenance therapy following treatment of duodenal ulcer: Administer lansoprazole 15 mg orally once daily. The comparative clinical trial period did not exceed 12 months. Treatment of NSAID-induced gastric ulcer: Administer lansoprazole 30 mg orally once daily for 8 weeks. The comparative clinical trial period did not exceed 8 weeks. Reduction of the risk of NSAID-induced gastric ulcer: Administer lansoprazole 15 mg orally once daily for 12 weeks. The comparative clinical trial period did not exceed 12 weeks. Short-term treatment of symptoms associated with gastroesophageal reflux disease: Administer lansoprazole 15 mg orally once daily for 8 weeks Short-term treatment of erosive reflux esophagitis: Administer lansoprazole 30 mg orally once daily for 8 weeks. Maintenance therapy following treatment of erosive reflux esophagitis: Administer lansoprazole 15 mg orally once daily. Pathological hypersecretory conditions, including Zollinger-Ellison syndrome: Lansoprazole dosing for pathological hypersecretory conditions varies by patient. Treatment in adults is usually initiated at 60 mg once daily. The dose should be adjusted according to the patient’s needs and may be continued as long as it is clinically effective. Doses of 90 mg per administration up to twice daily have been given. If the daily dose exceeds 120 mg, it should be divided. Since clearance of this medicine is reduced in elderly patients, dose adjustment is necessary. Do not exceed a daily dose of 30 mg. In patients with hepatic impairment, metabolism and excretion of this medicine may be delayed; administer cautiously, including consideration of dose adjustment.
Child dose
Children and adolescents aged 12 ∼ 17 years — short-term treatment of symptoms associated with non-erosive gastroesophageal reflux disease: 15 mg once daily for 8 weeks Children and adolescents aged 12 ∼ 17 years — short-term treatment of erosive reflux esophagitis: 30 mg once daily for 8 weeks Children aged 1 ∼ 11 years, 30 kg or less: 15 mg once daily for 12 weeks Children aged 1 ∼ 11 years, over 30 kg: 30 mg once daily for 12 weeks

Ingredients

Manufacturer
Kips Bio Pharma Co., Ltd.

Efficacy & effects

Treatment and prevention of gastroduodenal ulcers, Helicobacter pylori infection, gastroesophageal reflux disease, and excess gastric acid

  • Active duodenal ulcer
  • active benign gastric ulcer
  • recurrence of duodenal ulcers
  • NSAID-induced gastric ulcers
  • symptoms related to gastroesophageal reflux disease
  • erosive esophagitis
  • Zollinger-Ellison syndrome
  • pathological hypersecretion states
View approved original text

This medication is used for the short-term treatment of active duodenal ulcers and gastric ulcers. It also eradicates Helicobacter pylori infections to prevent recurrence of duodenal ulcers and is effective for maintenance therapy after treatment. It helps in the treatment of gastric ulcers caused by non-steroidal anti-inflammatory drugs (NSAIDs) and reduces the risk of occurrence. It is used for the short-term treatment and maintenance of gastroesophageal reflux disease and erosive esophagitis. Finally, it is effective for pathological hypersecretion states, including Zollinger-Ellison syndrome, making it useful for various gastrointestinal disorders.

How to take

Adult dose

This medicine should be administered before meals. For patients who have difficulty swallowing the medicine, open the capsule, mix the contents into a small amount of (60 mL) orange juice or tomato juice, and administer immediately. To ensure that the entire dose is taken, rinse the glass with twice or more the amount of juice and drink immediately. After opening this medicine, do not chew or crush it before taking it. Short-term treatment of active duodenal ulcer: Administer lansoprazole 15 mg orally once daily for 4 weeks. Short-term treatment of active benign gastric ulcer: Administer lansoprazole 30 mg orally once daily for 8 weeks. Eradication of Helicobacter pylori to reduce recurrence of duodenal ulcer: Administer lansoprazole 30 mg with clarithromycin 250 ∼ 500 mg and amoxicillin 1,000 mg twice daily (every 12 hours) for 7 days. Administration may be continued for up to 14 days if necessary. Eradication of Helicobacter pylori to reduce recurrence of duodenal ulcer: Administer lansoprazole 30 mg in combination with amoxicillin 1,000 mg 3 times daily (every 8 hours) for 14 days. Maintenance therapy following treatment of duodenal ulcer: Administer lansoprazole 15 mg orally once daily. The comparative clinical trial period did not exceed 12 months. Treatment of NSAID-induced gastric ulcer: Administer lansoprazole 30 mg orally once daily for 8 weeks. The comparative clinical trial period did not exceed 8 weeks. Reduction of the risk of NSAID-induced gastric ulcer: Administer lansoprazole 15 mg orally once daily for 12 weeks. The comparative clinical trial period did not exceed 12 weeks. Short-term treatment of symptoms associated with gastroesophageal reflux disease: Administer lansoprazole 15 mg orally once daily for 8 weeks Short-term treatment of erosive reflux esophagitis: Administer lansoprazole 30 mg orally once daily for 8 weeks. Maintenance therapy following treatment of erosive reflux esophagitis: Administer lansoprazole 15 mg orally once daily. Pathological hypersecretory conditions, including Zollinger-Ellison syndrome: Lansoprazole dosing for pathological hypersecretory conditions varies by patient. Treatment in adults is usually initiated at 60 mg once daily. The dose should be adjusted according to the patient’s needs and may be continued as long as it is clinically effective. Doses of 90 mg per administration up to twice daily have been given. If the daily dose exceeds 120 mg, it should be divided. Since clearance of this medicine is reduced in elderly patients, dose adjustment is necessary. Do not exceed a daily dose of 30 mg. In patients with hepatic impairment, metabolism and excretion of this medicine may be delayed; administer cautiously, including consideration of dose adjustment.

Child dose

Children and adolescents aged 12 ∼ 17 years — short-term treatment of symptoms associated with non-erosive gastroesophageal reflux disease: 15 mg once daily for 8 weeks Children and adolescents aged 12 ∼ 17 years — short-term treatment of erosive reflux esophagitis: 30 mg once daily for 8 weeks Children aged 1 ∼ 11 years, 30 kg or less: 15 mg once daily for 12 weeks Children aged 1 ∼ 11 years, over 30 kg: 30 mg once daily for 12 weeks

Precautions

This medication should not be used by individuals with hypersensitivity to certain ingredients or those allergic to benzimidazoles. Those allergic to penicillin or macrolide antibiotics should also avoid this medication. It is advisable to avoid this drug if you are taking certain heart-related medications, are pregnant, or have lactose intolerance. Patients with a history of drug allergies, poor liver function, elderly individuals, breastfeeding women, and children should use this drug with caution. Serious side effects such as severe allergic reactions, blood disorders, liver dysfunction, and skin rashes may occur, so if any abnormal symptoms appear, discontinue usage immediately and consult a physician. Regular monitoring is necessary as long-term use may lead to vitamin B12 deficiency or increased fracture risk. This medication inhibits gastric acid secretion and may affect the absorption of other drugs, so be cautious of interactions with other medications. Consultation with a physician is necessary, especially when taking certain antivirals, antibiotics, or anticoagulants. It is safest to avoid use during pregnancy as it may affect the fetus, and breastfeeding women should either avoid using it or discontinue breastfeeding. In children, safety and effectiveness have not been adequately established, so follow professional guidance. In cases of overdose, gastric lavage or treatment according to symptoms may be necessary, and it should be kept out of reach of children. This medication should be used only after confirming that symptoms such as gastric ulcers or gastrointestinal bleeding are not caused by malignancy, and it is preferable to use the minimum effective dose for the appropriate duration during long-term use. Caution is needed while driving or operating machinery, as dizziness or drowsiness may occur during usage.

Side effects

Anaphylactic reaction, generalized rash, facial swelling, respiratory distress, shock, pancytopenia, agranulocytosis, hemolytic anemia, granulocytopenia, thrombocytopenia, anemia, jaundice, elevated AST, elevated ALT, toxic hepatic dysfunction, toxic epidermal necrolysis, Stevens-Johnson syndrome, DRESS syndrome, interstitial pneumonia, fever, cough, abnormal lung sounds, interstitial nephritis, acute renal failure, pseudomembranous colitis, bloody stool, abdominal pain, diarrhea, headache, abdominal distension, allergic reaction, back pain, weakness, candidiasis, neoplasm, chills, chest pain, edema, fever, flu-like symptoms, halitosis, infection, fatigue, neck stiffness, neck pain, pelvic pain, angina, arrhythmia, bradycardia, tachycardia, cerebrovascular accident, cerebral infarction, hypertension, hypotension, migraine, myocardial infarction, palpitations, vasodilation, syncope, asthma, bronchitis, increased cough, epistaxis, hemoptysis, hiccups, pneumonia, upper respiratory tract infection, laryngeal tumor, pulmonary fibrosis, pharyngitis, pleural disorder, respiratory disorder, rhinitis, sinusitis, acne, hair loss, itching, rash, urticaria, contact dermatitis, skin dryness, nail disease, skin cancer, skin disease, sweating, abnormal vision, amblyopia, blepharitis, cataract, conjunctivitis, dry eye, ear disease, eye disease, glaucoma, abnormal olfaction, photophobia, retinal degeneration, loss of taste, blurred vision, deafness, ocular pain, otitis media, taste disturbance, tinnitus, visual field constriction, micturition disorder, renal pain, penile disease, testicular disease, urethral pain, polyuria, frequent urination, urinary retention, menstrual irregularities, chest tenderness, chest expansion, gynecomastia, diabetes, hematuria, erectile dysfunction, nephrolithiasis, abdominal pain, nausea, vomiting, gastric candidiasis, rectal disease, rectal bleeding, (ulcerative) stomatitis, tongue disease, glossitis, gum bleeding, post-prandial hypoglycemia, (ulcerative) colitis, headache, dizziness, insomnia, paralysis, depressive state, elevated triglycerides, elevated uric acid, elevated total cholesterol, decreased total cholesterol, proteinuria, glycosuria, fatigue, fracture, myositis, erythema multiforme, acute generalized pustular psoriasis, speech disorder, urinary retention, hepatotoxicity, pancreatitis, taste disturbance, aplastic anemia, leukopenia, neutropenia, thrombocytopenic purpura, eosinophilia, hypomagnesemia, Clostridium difficile-associated diarrhea, weakness, hyponatremia, paralysis of the tongue and lips, limb paralysis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air or moisture, so it must be stored in a tightly sealed container. It is best to keep it at room temperature between 1°C and 30°C, which will help maintain the effectiveness of the medication for an extended period.

Appearance and packaging

Appearance

A hard capsule filled with white granules that are white to light brown, with a green upper part and a white lower part.

Package unit

28 capsules/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.